Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OLI.VAS

Financiado

Cerrado

The Oligo Vascular interface understanding its properties and functions

Oligodendrocytes (OLs) are the glia cells that produce myelin in the central nervous system (CNS). Despite the severe outcome of demyelinating diseases, like multiple sclerosis (MS), little is known about the mechanisms by which m... ver más

31/05/2026

UKB

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITATSKLINIKUM BONN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-24

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UKB

1.61M€ | Lider

FERTIBERIA

585.78K€ | Participante

UHEI

390.85K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MecMy Mechanisms of Myelination Elucidating the Diversity of Oli... 1M€ Cerrado

MYELIN Mechanisms of myelin biogenesis and repair 1M€ Cerrado

OligProcessExtension Study of proteins involved in oligodendrocyte process extens... 160K€ Cerrado

SAF2016-75292-R REGULACION DE LOS PROCESOS DE MIELINIZACION Y REMIELINIZACIO... 411K€ Cerrado

MODOPCFATE Modulation of oligodendrocyte precursor cells differentiatio... 45K€ Cerrado

SAF2012-40023 MIELINA: DESDE LA OLIGODENDROGENESIS A LAS ENFERMEDADES DESM... 187K€ Cerrado

Duración del proyecto: 75 meses Fecha Inicio: 2020-02-24
Fecha Fin: 2026-05-31

Líder del proyecto

UNIVERSITATSKLINIKUM BONN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Oligodendrocytes (OLs) are the glia cells that produce myelin in the central nervous system (CNS). Despite the severe outcome of demyelinating diseases, like multiple sclerosis (MS), little is known about the mechanisms by which myelin is disrupted or why remyelination fails in disease. Thus, a substantial advance in the understanding of oligodendrocyte biology and myelin pathology is required in order to develop successful treatments for demyelinating diseases. Recent research indicates that apart from delivering oxygen and nutrients, blood vessels are active regulators of organ function. Our recent work supports the existence of an oligo-vascular interface where vessels directly control oligodendrogenesis. However, mechanistic insights of the interaction between OLs and the vasculature are lacking. Based on the innovative hypothesis that proper generation and OL functionality depends on active crosstalk with the vasculature, the OLI.VAS project will now tackle the challenge to characterize in depth the interaction between OLs and the vasculature during development and demyelinating diseases. To achieve this goal, two complementary multidisciplinary research tracks are pursued: Research track 1: Deconstructing and reconstructing the oligo-vascular interface to unravel the relationship of oligodendrocyte lineage cells with the vasculature Research track 2: Studying the oligo-vascular interface in white matter lesions. Modulating the vasculature to prevent de-myelination or promote of re-myelination Both tracks combine cutting edge technology in single cell and spatial transcriptomics, bioinformatics, 3D imaging, in vitro and ex vivo tissue culture, mouse genetics and MS patient samples. OLI.VAS will deliver new insights into the role of the vasculature as a regulator of oligodendrogenesis and myelination and thus generate major scientific breakthroughs in an area that is highly relevant for diseases such as MS, which affects more than 600000 patients in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores